Expert recommendations outline how crinecerfont may help reduce glucocorticoid exposure in children with classic CAH.
Patricia Y. Fechner, MD
Advertisement
Patricia Y. Fechner, MD, Medical Director, DSD Program; Medical Director, CAH Program and Co-Director, Turner Syndrome Clinic, Seattle Children’s.
Articles by Patricia Y. Fechner, MD
Patricia Fechner, MD, discusses how crinecerfont may reduce glucocorticoid exposure in pediatric CAH
Expert recommendations outline how crinecerfont may help reduce glucocorticoid exposure in children with classic CAH.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Julie Khlevner, MD, discusses the impact of FDA-approved LINZESS for functional constipation
2
Supporting children with hidradenitis suppurativa beyond medical treatment, with Colleen Cotton, MD
3
Top 5 pediatric health headlines you missed in May 2026
4
Jamie Wood, MD, on the significance of the Afrezza approval for pediatric diabetes
5